SecBot SecBot
SECBOTREPLAY Home › Report › BIIB

BIIB · Biogen acquired RayThera Inc., a private immunology biotech, adding a…

Biogen Inc. · PRESS-RELEASE filed Aug 6, 2026 at 18:15 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 6, 2026 at 18:15 ET

Biogen acquired RayThera Inc., a private immunology biotech, adding a Phase 1 small-molecule program and pipeline assets to diversify beyond its core neurology focus. The deal's financial terms were not disclosed, limiting near-term P&L impact, but it signals continued strategic investment in immunology as a growth area.

  • Acquisition of privately held RayThera Inc., focused on small-molecule immunology therapies.
  • Lead program entered Phase 1 development in July 2026.
  • Financial terms (upfront, milestones, deal value) not disclosed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access